3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Endometrial Neoplasms
7
Ovarian Neoplasms
6
Neoplasms
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Sarcoma, Clear Cell
1
Sarcoma
1
Recurrence
1
Penile Neoplasms
1
Pathologic Complete Response
1
Neoplasms, Second Primary
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
MMRd/MSI-H Stage II-III Endometrial Cancer
1
Interventions
pembrolizumab
6
Mitotane
5
Cisplatin
5
cabozantinib
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
sodium thiosulfate
2
relacorilant
2
cixutumumab
2
cemiplimab
2
camrelizumab
2
apatinib
2
Radiotherapy
2
Nivolumab
2
Ipilimumab
2
Etoposide
2
Cytoreduction Surgical Procedures
2
milademetan
1
lenvatinib
1
gossypol acetic acid
1
dostarlimab
1
cabazitaxel
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Vincristine
1
Tamoxifen
1
Suramin
1
Sunitinib
1
Sorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adrenocortical Carcinoma
×
dostarlimab
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled